Listen on the go
    • Downloads

    View and download resources from this activity to support your learning and share with colleagues

    DOWNLOAD SLIDES
    DOWNLOAD PRACTICE AID
    DOWNLOAD SLIDES
    DOWNLOAD SLIDES
    DOWNLOAD SLIDES
    CORRECT!
    Next question
    Faculty & Disclosures
    Dr Matthew Matasar

    Rutgers Cancer Institute, New Brunswick, NJ, USA

    Dr Matthew Matasar is the chief of the Division of Blood Disorders at Rutgers Cancer Institute, New Brunswick, NJ, USA, and professor of medicine at Rutgers Robert Wood Johnson Medical School.read more

    He graduated from Harvard College and Harvard Medical School, Boston, MA, and moved to New York to train in medicine at the New York-Presbyterian Columbia University Irving Medical Center. After completing training in internal medicine, he served as a chief resident at Columbia-Presbyterian Medical Center while completing a master’s degree at the Mailman School of Public Health. Soon after, he joined Memorial Sloan Kettering Cancer Center to pursue advanced training in cancer medicine, and has been dedicated to caring for patients with lymphoma ever since. 

    In November 2022, Dr Matasar joined the Rutgers Cancer Institute of New Jersey and RWJBarnabas Health in New Brunswick. His research is focused on finding new and better ways to treat lymphoma, particularly high-risk aggressive lymphomas and certain uncommon non-Hodgkin lymphomas. Together with his research team, he wants to develop better strategies for protecting and preserving the health of survivors, through better understanding of the long-term impacts of treatments on patients.

    Dr Matasar contributes to the oncology community as a member of the board of the New Jersey chapter of the Leukemia and Lymphoma Society and as a member of the American Society of Hematology’s National Committee on Quality.

    Dr Matthew Matasar discloses: Advisory board or panel fees from Genentech and Merck. Consultancy fees from Bayer, Juno Therapeutics, Roche/Genentech, Seattle Genetics, Takeda and Teva. Grants/research support from Bayer, GM Biosciences, Immunovaccine Therapeutics, Janssen, Pharmacyclics, Roche/Genentech and Seagen. Stock/shareholder (self-managed) in Merck. Other financial or material support from ADC Therapeutics, AstraZeneca, Bayer, BMS, Celgene, Epizyme, Immunovaccine Therapeutics, IMV Therapeutics, Janssen, Kite Pharma, Pharmacyclics, Regeneron, Roche, Seagen and Takeda.
    Dr Amitkumar Mehta

    O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA

    Dr Amitkumar Mehta is an associate professor at the O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham (UAB), AL, USA. read more

    He received his medical degree from Baroda Medical College, India, and completed his internship and residency at the Providence Hospital-George Washington University, DC, USA, before accepting a fellowship position in haematology and oncology at the UAB. During his fellowship training, he focused on various translational projects, including the novel prognostic role of circulating free telomeres in patients with acute myeloid leukemia.

    Following his fellowship training, Dr Mehta joined the faculty at the UAB in 2014. His research now focuses on experimental therapeutics in haematological malignancies, especially lymphomas and chimeric antigen receptor (CAR) T-cell therapies. He has been a principal investigator on a number of clinical trials investigating the efficacy and safety of CAR T-cell therapy for treating lymphomas. He is currently the director of both the lymphoma and CAR-T cell therapy programmes at UAB, and associate director of the Phase I Program at O’Neal Comprehensive Cancer Center at UAB.

    Dr Mehta is a member of the American Society of Clinical Oncology and the American Society of Hematology, and board certified in medical oncology and haematology by the American Board of Internal Medicine.

    Dr Amitkumar Mehta discloses: Advisory board or panel fees from BeiGene, Gilead, Incyte, MorphoSys and Seagen. Consultancy fees from ADC Therapeutics, Kyowa Kirin, Roche/Genentech and TG Therapeutics. Grants/research support from Bristol Myers Squibb, Forty Seven Inc., Gilead, Incyte, Juno Therapeutics and Takeda. Speaker’s bureau fees from BeiGene, Incyte, Ipsen, Kyowa Kirin and MorphoSys. Other financial or material support from ADC Therapeutics, Affimed, Bristol Myers Squibb, Celgene, Gilead, Innate Pharma, Kite Pharma, Merck, Roche/Genentech, Seagen and TG Therapeutics. 
    touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Lymphoma

    An Introduction to Lymphoma

    Lymphoma is one of the ten most common malignancies worldwide. While some lymphomas are curable, the treatment of relapsed and refractory disease remains a substantial challenge. Recent advances have led to the development of a number of new treatment strategies, including novel antibodies targeting surface antigens, small molecular inhibitors targeting oncogenic signalling pathways and tumour suppressors, and immune checkpoint inhibitors. Chimeric antigen receptor (CAR) T-cells offer the potential for personalised therapy. The emergence of so many new therapeutic options have raised challenges in terms of optimal sequencing and combined approaches, and have highlighted the need for biomarkers to predict therapeutic response.

    Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    Lymphoma Content

    Lymphoma, Haematological Malignancies, Haematology
    Watch Time: 41 mins
    touchIN CONVERSATION
    Managing the practicalities of CAR T-cell therapies in patients with R/R MCL: Current considerations and future strategies
    CE/CME ACCREDITED Dr Matthew Matasar, Dr Amitkumar Mehta Translations available:

    Watch haemato-oncology experts discuss updates in managing R/R mantle cell lymphoma with CAR T-cell therapy.

    Learning objectives
    Learning Objectives
    • Review current treatment strategies for relapsed/refractory mantle cell lymphoma, including the role of CAR T-cell therapy
    • Formulate practical strategies for the management of CAR T-cell-associated toxicities and treatment failure in patients with relapsed/refractory mantle cell lymphoma
    • Discuss future considerations for optimizing CAR T-cell therapy in relapsed/refractory mantle cell lymphoma
    Haematological Malignancies, Lymphoma
    Watch Time: 39 mins
    touchIN CONVERSATION
    New horizons in R/R follicular lymphoma: Focus on risk stratification and managing the practicalities of CAR T-cell therapy
    CE/CME ACCREDITED Dr Nilanjan Ghosh, Dr Peter Riedell

    Watch haemato-oncology experts discuss updates in R/R follicular lymphoma, with a focus on CAR T-cell therapy.

    Learning objectives
    Learning Objectives
    • Apply prognostic and risk stratification strategies that predict treatment response and outcomes and help guide treatment decisions in FL
    • Describe the latest efficacy data for CAR T-cell therapies, their positioning in the treatment sequence for R/R FL, and key considerations for patient selection
    • Discuss the practical management of CAR T-cell-related toxicities and the importance of a multidisciplinary approach to care
    touchMEETING HIGHLIGHTS
    Connecting Symptoms to Quality of Life: The Importance of Considering Patient Wellbeing when Managing Cutaneous T-Cell Lymphoma (CTCL)
    For HCPs in: countries where mogamulizumab is licensed
    View Time: 37 mins Sponsored content

    Healthcare professionals are asked to report any adverse events via their national reporting system (see Section 4.8 of SmPC). In the UK reporting forms and information can be found at
    or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Kyowa Kirin Ltd on +44 (0)1896 664000, email: medinfo@kyowakirin.com

    Prescribing Information

    KKI/INT/MOG/0966
    Date of Preparation: November 2023
    Haematology, Lymphoma
    Developed by Touch
    ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023
    Watch Time: 4 mins

    ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss what previous clinical trials have taught us about […]

    Haematology, Lymphoma
    Developed by Touch
    Axicabtagene ciloleucel for the treatment of large B-cell lymphoma: Jason Westin, EHA 2023
    Watch Time: 2 mins

    Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved to treat patients with relapsed/refractory large B-cell lymphoma. We caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss the current treatment paradigm for large B-cell lymphoma, the limitations of current […]

    Haematological Malignancies, Lymphoma
    Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An expert interview with Umberto Vitolo

    Umberto Vitolo is a Haematology Consultant, Candiolo Cancer Institute, Fondazione del Piemonte per l’Oncologia, IRCCS, Candiolo (Torino), Italy. His research interests are haematological malignancies, primarily lymphoma. He is a member of the Italian Society of Haematology, the Italian Society of Experimental Haematology and the American Society of Haematology. He has authored many papers in peer-reviewed […]

    Haematological Malignancies, Leukaemia, Lymphoma
    Developed by Touch
    Jennifer Brown, ASH 2022: Zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma, ALPINE (phase III) results
    Watch Time: 3 mins

    The ALPINE study in patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma has shown that zanubrutinib may offer potential advantages over ibrutinib. In this touchONCOLOGY interview, we speak with Dr Jennifer Brown (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss the mechanism of action of zanubrutinib, its potential advantages over ibrutinib and the […]

    Lymphoma
    Developed by Touch
    William Townsend, EHA 2022: Final analysis of the GALLIUM study of obinutuzumab plus chemotherapy in follicular lymphoma
    Watch Time: 9 mins

    Dr William Townsend shares the latest data from the final analysis of the phase III GALLIUM study, which used the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab plus chemotherapy to  follicular lymphoma. The study compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma. The abstract ‘OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM […]

    Haematological Malignancies, Lymphoma
    Developed by Touch
    PART TWO: Mazyar Shadman, EHA 2022: MB-106 for the treatment of relapsed/refractory follicular lymphoma: Results of the phase I/II study
    Watch Time: 4 mins

    In Part Two of this interview, Dr Mazyar Shadman (Fred Hutchinson Cancer Center, Seattle, Was, USA) presents the results of the follicular lymphoma cohort from his ongoing phase I/II clinical trial investigating MB-106 for B-cell lymphoma/CLL. He discusses the positive efficacy and safety data and the next steps in the clinical development of MB-106. Abstract […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72